Clone:
REA269
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC
Alternative names:
VCAM1, INCAM-100

Extended validation for CD106 (VCAM-1) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA269
51-10C9++
STA++
Cells were incubated with an excess of purified unconjugated CD106 (VCAM-1) (REA269) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

View details
Flow cytometric comparison of different clones for CD106 (VCAM-1). Human peripheral blood mononuclear cells (PBMCs) were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Transcription Factor Staining Buffer Set followed by intracellular staining with CD106 (VCAM-1) antibodies. As a control, CD106 (VCAM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD106 (VCAM-1). Human peripheral blood mononuclear cells (PBMCs) were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Transcription Factor Staining Buffer Set followed by intracellular staining with CD106 (VCAM-1) antibodies. As a control, CD106 (VCAM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD106 (VCAM-1). Human peripheral blood mononuclear cells (PBMCs) were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Transcription Factor Staining Buffer Set followed by intracellular staining with CD106 (VCAM-1) antibodies. As a control, CD106 (VCAM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD106 (VCAM-1). Human peripheral blood mononuclear cells (PBMCs) were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Transcription Factor Staining Buffer Set followed by intracellular staining with CD106 (VCAM-1) antibodies. As a control, CD106 (VCAM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD106 (VCAM-1) (REA269). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD106 (VCAM-1) (REA269). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD106 (VCAM-1) (REA269). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD106 (VCAM-1) Antibody, anti-human, REAfinity™

Overview

Clone REA269 recognizes the CD106 antigen, a 110 kDa single chain type I glycoprotein, also known as vascular cell adhesion protein 1 (VCAM-1) or INCAM-100. CD106 is expressed on inflamed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflamed tissue. Upregulation of CD106 in endothelial cells by inflammatory stimuli and cytokines occurs as a result of increased gene transcription. Primarily, CD106 is an endothelial ligand for very late antigen-4 (VLA-4) or integrin α-4/β-7 and mediates both adhesion and signal transduction. The interactions play a pathophysiologic role in leukocyte adhesion, transmigration, and co-stimulation of T cell proliferation.
Additional information: Clone REA269 displays negligible binding to Fc receptors.

Alternative names

VCAM1, INCAM-100

Detailed product information

Technical specifications

CloneREA269
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD106 (VCAM-1)
Alternative names of antigenVCAM1, INCAM-100
Molecular mass of antigen [kDa]79
Distribution of antigendendritic cells, endothelial cells, macrophages
Entrez Gene ID7412
RRIDAB_2857707, AB_2801824, AB_2801820, AB_2801918, AB_2654443, AB_2654444, AB_2654445, AB_2654446, AB_2654447, AB_2654448, AB_2654449, AB_2654450, AB_2857709

References for CD106 (VCAM-1) Antibody, anti-human, REAfinity™

Publications

  1. Osborn, L. et al. (1992) Activated endothelium binds lymphocytes through a novel binding site in the alternately spliced domain of vascular cell adhesion molecule-1. J. Exp. Med. 176(1): 99-107
  2. Johnson, L. A. et al. (2008) Cell traffic and the lymphatic endothelium. Ann. N. Y. Acad. Sci. 1131: 119-133
  3. Barreiro, O. et al. (2002) Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157(7): 1233-1245

Related products for
CD106 (VCAM-1) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?